Drug Trial Radar · NCT04490915
Global Safety and Efficacy Registration Study of Crinecerfont for Congenital Adrenal Hyperplasia
Last checked: Nov 19, 2026Latest source record: May 11, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
182
Actual
Start
Dec 16, 2020
Primary completion
Jul 19, 2023
Study completion Aug 2027
Sponsor
- Lead sponsor
- Neurocrine BiosciencesNeurocrine Biosciences (NBIX)
- Sponsor type
- Industry
- First posted
- Jul 29, 2020
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, care provider, investigator)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a Phase 3 study to evaluate the efficacy, safety, and tolerability of crinecerfont versus placebo administered for 24 weeks in approximately 165 adult participants with classic CAH due to 21-hydroxylase deficiency. The study consists of a 24-week randomized, double-blind, placebo-controlled period, followed by 1 year of active treatment with crinecerfont. Subsequently, participants may elect to participate in the open-label extension (OLE) period. The duration of participation in the study is approximately 20 months for the core study and will be a variable amount of time per participant for the OLE (estimated to be approximately 3 years).
Conditions
- Congenital Adrenal Hyperplasia
Interventions
CrinecerfontDrug
CRF type 1 receptor antagonist
PlaceboDrug
Non-active dosage form
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percent Change From Baseline in Glucocorticoid Daily Dose at Week 24Time frame: Baseline, Week 24
Locations
70 sites in 18 countries. Site status is shown where the registry gives one.
Neurocrine Clinical Site
Los Angeles, California
Neurocrine Clinical Site
San Diego, California
Neurocrine Clinical Site
San Francisco, California
Neurocrine Clinical Site
Aurora, Colorado
Neurocrine Clinical Site
Atlanta, Georgia
Neurocrine Clinical Site
Indianapolis, Indiana
Neurocrine Clinical Site
Bethesda, Maryland
Neurocrine Clinical Site
Boston, Massachusetts
Neurocrine Clinical Site
Ann Arbor, Michigan
Neurocrine Clinical Site
Minneapolis, Minnesota
Neurocrine Clinical Site
Rochester, Minnesota
Neurocrine Clinical Site
St Louis, Missouri
Neurocrine Clinical Site
Great Neck, New York
Neurocrine Clinical Site
New York, New York
Neurocrine Clinical Site
Winston-Salem, North Carolina
Neurocrine Clinical Site
Tulsa, Oklahoma
Neurocrine Clinical Site
Philadelphia, Pennsylvania
Neurocrine Clinical Site
Pittsburgh, Pennsylvania
Neurocrine Clinical Site
Dallas, Texas
Neurocrine Clinical Site
Seattle, Washington
Neurocrine Clinical Site
Graz, Austria
Neurocrine Clinical Site
Vienna, Austria
Neurocrine Clinical Site
Brussels, Belgium
Neurocrine Clinical Site
Leuven, Belgium
Neurocrine Clinical Site
Sofia, Bulgaria
Neurocrine Clinical Site
Sofia, Bulgaria
Neurocrine Clinical Site
Halifax, Nova Scotia, Canada
Neurocrine Clinical Site
Hradec Králové, Czechia
Neurocrine Clinical Site
Angers, France
Neurocrine Clinical Site
Grenoble, France
Neurocrine Clinical Site
Le Kremlin-Bicêtre, France
Neurocrine Clinical Site
Nantes, France
Neurocrine Clinical Site
Paris, France
Neurocrine Clinical Site
Paris, France
Neurocrine Clinical Site
Dresden, Germany
Neurocrine Clinical Site
Essen, Germany
Neurocrine Clinical Site
Frankfurt, Germany
Neurocrine Clinical Site
Leipzig, Germany
Neurocrine Clinical Site
Munich, Germany
Neurocrine Clinical Site
Athens, Greece
Showing 40 of 70 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.